This website uses cookies

This website uses cookies to ensure you get the best experience. By using our website, you agree to our Privacy Policy

International In-house Counsel Journal logoInternational In-house Counsel Journal logo

The Compulsory Licensing in Russia: The First Precedent Lessons Learned

Abstract

The compulsory license mechanism in Russia had been described in the Civil Code of the Russian Federation for a long time. However, there had been no real cases of granting of compulsory licensing till recently. In 2018 the Russian court first time in history approved for use within the territory of Russia the compulsory license of the drug Revlimid® (INN lenalidomide) protected by the patent of Celgene, an American pharmaceutical company.

Read Paper

Author

Portrait image of Elvira Dubovskaya
Elvira Dubovskaya
Fulbright Scholar, N/A, Russia

Elvira Dubovskaya graduated with honors from Lomonosov Moscow State University, Faculty of Law (J.D. equivalent) with emphasis in International Public Law. Being a Fulbright scholar, she obtained her LL.M. degree in International Business and Economic law with distinction from Georgetown University Law Center, Washington, DC, USA in 2014. She represented the Russian Federation in 33rd Telder`s Moot Court Competition in Hague, the Netherlands in 2010. Elvira has several publications in various professional journals on IP and antitrust law issues. She has been working in pharmaceutical industry since 2011.

Company

N/A

n/a

Related Papers

Licensing of Trademarks in India: An Historical Overview
At its simplest, trademark licensing is permission granted by a trademark owner (licensor) to another (licensee) to use the licensor’s trademark on mutually agreed terms and conditions. Consistent with the...Read more
Portrait image of Amit Sindhwani
Amit Sindhwani
Head of IPR, Usha International, India
Portrait image of Rajendra Kumar
Rajendra Kumar
Founding Partner RKR & Partners, RKR & Partners, India
Patent Strategies for Attenuated Pathogen Vaccines
Malaria is a major health concern for people traveling to and living in malaria-endemic areas, causing 249 million clinical cases and 608,000 deaths in 2022, numbers essentially unchanged over the...Read more
Portrait image of David Dolberg
David Dolberg
Senior Director of Intellectual Property, Sanaria Inc., USA
Ways to Avoid Having your Patents Cellected*
The Court of Appeals for the Federal Circuit caused frustrations when it decided to affirm the U.S. Patent Office’s findings that claims in four patents were unpatentable because they are...Read more
Portrait image of Tom Irving
Tom Irving
Partner, Marbury Law Group, USA
Portrait image of Michelle E. O'Brien
Michelle E. O'Brien
Partner, Marbury Law Group, USA
Portrait image of Xiaoguang Michelle Gao
Xiaoguang Michelle Gao
Associate VP - Assistant General Patent Counsel , Eli Lilly and Company, USA
Supported Studies Quid Pro Quo
Many pharmaceutical companies (hereinafter Companies or Company) recognize the importance of supporting external studies and the role they play in fulfilling patients’ needs. High standard ethical research conducted by external...Read more
Portrait image of Ann Turi
Ann Turi
Senior Legal Counsel, Legal and Compliance R&D and Medical Legal Team, Gsk, USA